Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (91-100 of 174) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patientsAntonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Blood|June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-AnalysisPhilip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.
Haematologica|March 25, 2014
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma NetworkNiels W C J van de Donk, Antonio Palumbo, Hans Erik Johnsen, et al.
Stem Cell Research & Therapy|April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party studyPellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
Blood|September 21, 2022
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trialsBruno Paiva, Irene Manrique, Meletios A Dimopoulos, et al.
Leukemia|June 9, 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Pageof 18

Showing results (91-100 of 174) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patientsAntonio Palumbo, Francesca Gay, Patrizia Falco, et al.
Blood|June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-AnalysisPhilip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.
Haematologica|March 25, 2014
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma NetworkNiels W C J van de Donk, Antonio Palumbo, Hans Erik Johnsen, et al.
Stem Cell Research & Therapy|April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party studyPellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
Blood|September 21, 2022
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trialsBruno Paiva, Irene Manrique, Meletios A Dimopoulos, et al.
Leukemia|June 9, 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, et al.
Blood|January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Pageof 18